Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 10;12(5):674-682.
doi: 10.4103/idoj.IDOJ_113_21. eCollection 2021 Sep-Oct.

Systemic Management of Psoriasis Patients in Indian Scenario: An Expert Consensus

Murlidhar Rajagopalan  1 , Manas Chatterjee  2 , Abhishek De  3 , Sunil Dogra  4 , Satyaki Ganguly  5 , Bikash Ranjan Kar  6 , Nina Madnani  7 , Shekhar Neema  8 , S G Parasramani  9 , Krina Patel  10 , Sushil Tahiliani  11
Affiliations

Systemic Management of Psoriasis Patients in Indian Scenario: An Expert Consensus

Murlidhar Rajagopalan et al. Indian Dermatol Online J. .

Abstract

Background: Psoriasis is a common inflammatory disease with significant comorbidities, and regardless of its extent, it affects the patients' quality of life. The various modalities of treating psoriasis comprise topical or systemic medications, phototherapy, and an array of biologic agents. There is a lack of Indian recommendations on the management of psoriasis with these different modalities and challenges faced by the clinicians in day-to-day practice.

Aim: To develop India-specific consensus for systemic management of patients with moderate-to-severe psoriasis.

Method and results: A panel of dermatology experts, based on the evidence and international recommendations, coupled with their own clinical experience, developed recommendations for systemic management of patients with moderate-to-severe psoriasis.

Conclusion: These recommendations are meant to provide guidance in terms of choice of systemic therapies, dosing, effectiveness, and safety. It also addresses clinical challenges that may be experienced during psoriasis management.

Keywords: Biologics; Indian consensus; conventional; psoriasis; systemic.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Methodology of the Expert Consensus Recommendation
Figure 2
Figure 2
Expert consensus on eligibility criteria for biologics
Figure 3
Figure 3
Expert Consensus Recommendations on Addressing Reduction of Efficacy
See this image and copyright information in PMC

References

    1. Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7:471–80. - PMC - PubMed
    1. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595–601. - PubMed
    1. Kanwar AJ, Yadav S, Dogra S. Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics? Indian J Dermatol Venereol Leprol. 2010;76:622–33. - PubMed
    1. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–85. - PMC - PubMed
    1. Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2016;30(Suppl 2):1–18. - PubMed